731018-54-5

Basic information

• Product Name: Carbamic acid, (5-fluoro-2-thiazolyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (5-fluoro-2-thiazolyl)-, 1,1-dimethylethyl ester (9CI);tert-butyl5-fluorothiazol-2-ylcarbamate;Carbamic acid, (5-fluoro-2-thiazolyl)-, 1,1-dimethylethyl ester;Carbamic acid, N-(5-fluoro-2-thiazolyl)-, 1,1-dimethylethyl ester;(5-Fluoro-2-thiazolyl)carbamic acid 1,1-dimethylethyl ester;tert-butyl 5-fluoro-1,3-thiazol-2-ylcarbamate;N-(5-fluoro-2-thiazolyl)-, 1,1-diMethylethyl ester;(5-Fluoro-thiazol-2-yl)-carbaMic acid tert-butyl ester
• CAS NO: 731018-54-5
• Molecular Formula: C₈H₁₁FN₂O₂S
• Molecular Weight: 218.2485432
• Product Categories: N-BOC
• Mol File: 731018-54-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Density: 1.32g/cm³
• Refractive Index: 1.549
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.47±0.70(Predicted)
• CAS DataBase Reference: Carbamic acid, (5-fluoro-2-thiazolyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (5-fluoro-2-thiazolyl)-, 1,1-dimethylethyl ester (9CI)(731018-54-5)
• EPA Substance Registry System: Carbamic acid, (5-fluoro-2-thiazolyl)-, 1,1-dimethylethyl ester (9CI)(731018-54-5)

Safety Data

• Hazardous Substances Data: 731018-54-5(Hazardous Substances Data)

Usage

General Description

Carbamic acid, (5-fluoro-2-thiazolyl)-, 1,1-dimethylethyl ester (9CI), also known as ethyl (5-fluoro-2-thiazolyl)carbamate, is a chemical compound with the molecular formula C8H10FN2O2S. It is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various medications. Carbamic acid, (5-fluoro-2-thiazolyl)-, 1,1-dimethylethyl ester (9CI) is also known for its fungicidal and pesticidal properties, making it a valuable component in agricultural products. However, it is important to handle this chemical with caution as it can be harmful if ingested, inhaled, or in contact with the skin and eyes. Proper safety measures and protective equipment should be used when working with this compound to minimize the risk of exposure.

InChI:InChI=1/C8H11FN2O2S/c1-8(2,3)13-7(12)11-6-10-4-5(9)14-6/h4H,1-3H3,(H,10,11,12)

Upstream product

• 170961-15-6 tert-butyl 1,3-thiazole-2-yl-carbamate 
• 405939-39-1 tert-butyl 5-bromothiazol-2-ylcarbamate 
• 745078-03-9 2-tert-butoxycarbonylamino-thiazole-5-carboxylic acid methyl ester 
• 302964-02-9 2-[(tert-butoxycarbonyl)amino]-1,3-thiazole-5-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 745053-64-9 5-fluoro-1,3-thiazol-2-amine hydrochloride 
• 64588-82-5 5-fluoro-1,3-thiazol-2-amine 

Relevant articles and documents

Practical synthesis of 2-amino-5-fluorothiazole hydrochloride

The first synthesis of 2-amino-5-fluorothiazole hydrochloride is reported from 2-aminothiazole. The synthesis proceeds in 35% overall yield, involves no chromatographic purification, and has been employed to prepare multikilogram quantities of the title c

METHOD OF MAKING AZAINDAZOLE DERIVATIVES

Disclosed are methods, reagents, and intermediates useful for making azaindazole derivatives, which may be used to modulate Glucokinase. The disclosed methods and materials are generally useful for making halo-esters and sulfonyl-substituted compounds.

Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators

A series of N-thiazole substituted arylacetamides were designed on the basis of metabolic mechanism of the aminothiazole fragment as glucokinase (GK) activators for the treatment of type 2 diabetes. Instead of introducing a substituent to block the metabolic sensitive C-5 position on the thiazole core directly, a wide variety of C-4 or both C-4 and C-5 substitutions were explored. Compound R-9k bearing an iso-propyl group as the C-4 substituent was found possessing the highest GK activation potency with an EC50 of 0.026 μM. This compound significantly increased both glucose uptake and glycogen synthesis in rat primary cultured hepatocytes. Moreover, single oral administration of compound R-9k exerted significant reduction of blood glucose levels in both ICR and ob/ob mice. These promising results indicated that compound R-9k is a potent orally active GK activator, and is warranted for further investigation as a new anti-diabetic treatment.